Randomized phase III trial of amrubicin vs. carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer
Phase 3
- Conditions
- Extensive-disease small-cell lung cancer (ED-SCLC)
- Registration Number
- JPRN-jRCT1080220200
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Extensive-disease small-cell lung cancer
- Aged 70 years or elder
- Performance status of 0-2
- No prior chemotherapy
etc.
- Prior therapy for primary lesion
- Pneumonitis and/or pulmonary fibrosis
- Active concomitant malignancy
etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method